Kventiax Sr

Quetiapine, the active ingredient in Kventiax Sr, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia, bipolar I disorder (both manic and depressive phases) and as adjunctive therapy for major depressive disorder in adult patients.

GNH USA supplies Kventiax Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine is an atypical antipsychotic used across several psychiatric conditions. - Schizophrenia: helps reduce psychotic symptoms such as hallucinations and delusions. - Bipolar I disorder (manic and depressive episodes): stabilises mood and prevents relapse of manic or depressive swings. - Adjunctive treatment of major depressive disorder: enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to discomfort. - Constipation: infrequent or difficult bowel movements. - Weight gain: increase in body weight over time. - Orthostatic hypotension: drop in blood pressure upon standing. - Elevated cholesterol or triglycerides: changes in lipid profile.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements, especially of the face. - Agranulocytosis: severe reduction in white blood cells. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Severe allergic reactions: rash, swelling, or breathing difficulty.

Before prescribing quetiapine, clinicians should consider several safety factors. - Cardiovascular assessment: monitor blood pressure and heart rate, especially in patients with pre‑existing hypertension. - Metabolic monitoring: check weight, glucose, and lipid levels regularly. - CNS depression: advise caution when combined with other sedatives or alcohol. - Elderly patients: start at low doses and watch for increased sensitivity to side effects. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Quetiapine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels, raising toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): can cause excessive sedation or respiratory depression.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce quetiapine concentrations, diminishing therapeutic effect. - Antihypertensives: additive blood‑pressure‑lowering effect may lead to orthostatic hypotension. - Anticholinergic agents: may exacerbate dry mouth and constipation.